1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
4,250 | 4,354 | 11:35 | |
4,198 | 4,388 | 20.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Börsennews zur PHASEBIO PHARMACEUTICALS Aktie und weiteren Hot Stocks erhalten | |||||
| 26.08. | PhaseBio Pharmaceuticals, Inc.: PhaseBio Announces Presentation of PB2452 Data at ESC Congress 2019 | 5 | GlobeNewswire (USA) | ||
| 14.08. | PhaseBio Pharmaceuticals Inc - 10-Q, Quaterly Report | - | SEC Filings | ||
| 14.08. | PhaseBio Pharmaceuticals Inc - 8-K, Current Report | - | SEC Filings | ||
| 01.07. | PhaseBio Pharmaceuticals Inc - 8-K, Current Report | - | SEC Filings | ||
| 18.06. | The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale | 3 | Benzinga.com | ||
| 17.06. | PhaseBio +12% on prelim PB2452 data | 1 | Seeking Alpha | ||
| 17.06. | PhaseBio Pharmaceuticals Inc - 8-K, Current Report | - | SEC Filings | ||
| 09.05. | PhaseBio Pharmaceuticals Inc - 8-K, Current Report | - | SEC Filings | ||
| 02.05. | PhaseBio Pharmaceuticals, Inc.: PhaseBio To Report First Quarter 2019 Financial Results and Recent Corporate Progress ... | 1 | GlobeNewswire (USA) | ||
| 23.04. | Wacker Biotech und PhaseBio unterzeichnen Lizenzvereinbarung zur Herstellung eines Antikörperfragments | 28 | CHEManager | ||
| 17.04. | PhaseBio's Latest FDA Designation Moves It One Step Closer To Potential Approval | 3 | Seeking Alpha | ||
| 17.04. | Why I've Started A Small Short In PhaseBio Pharmaceuticals | 4 | Seeking Alpha | ||
| 16.04. | PhaseBio Pharmaceuticals, Inc.: PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise ... | 1 | GlobeNewswire (USA) | ||
| 12.04. | PhaseBio down 5% on pricing stock offering | 2 | Seeking Alpha | ||
| 12.04. | PhaseBio Pharmaceuticals, Inc.: PhaseBio Announces Pricing of Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 10.04. | The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering | 4 | Benzinga.com | ||
| 10.04. | PhaseBio Pharmaceuticals Inc - 8-K, Current Report | - | SEC Filings | ||
| 09.04. | PhaseBio Pharmaceuticals, Inc.: PhaseBio Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 09.04. | PhaseBio files for equity offering; shares down 6% after hours | - | Seeking Alpha | ||
| 09.04. | PhaseBio Pharmaceuticals Inc - S-1, General form for registration of securities | - | SEC Filings |
Seite:
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 6,430 | -4,46 % | Medigene-Aktie: Das Bild verdüstert sich wieder | Aktuelle Kursentwicklungen bei der Medigene-Aktie lassen charttechnische Sorgen wachsen, dass der Biotech-Titel wieder nach unten abkippen könnte. Zuletzt war der Aktienkurs des süddeutschen Unternehmens... ► Artikel lesen | |
| AMGEN | 180,12 | +1,51 % | Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More | ||
| BIOFRONTERA | 5,960 | -1,16 % | DGAP-News: Biofrontera AG: Biofrontera beantragt die europäische Zulassungserweiterung von Ameluz zur Behandlung von aktinischen eratosen auf Extremitäten sowie Rumpf/Nacken (deutsch) | Biofrontera AG: Biofrontera beantragt die europäische Zulassungserweiterung von Ameluz zur Behandlung von aktinischen Keratosen auf Extremitäten sowie Rumpf/ Nacken
DGAP-News: Biofrontera AG / Schlagwort(e):... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 9,469 | -1,53 % | Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the publication in Nature Biotechnology of a manuscript by Jeffrey Miller, Ph.D., and colleagues at Sangamo,... ► Artikel lesen | |
| TREVENA | 0,931 | +2,26 % | TREVENA INC - 8-K, Current Report | ||
| SAREPTA THERAPEUTICS | 74,72 | -3,36 % | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm | New York, New York--(Newsfile Corp. - September 13, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) ("Sarepta" or... ► Artikel lesen | |
| GERON | 1,280 | -0,14 % | Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why | ||
| BIOCRYST PHARMACEUTICALS | 2,552 | -2,98 % | BioCryst up 4% on extended timeline for debt financing | ||
| SPARK THERAPEUTICS | 92,87 | -0,04 % | Spark Therapeutics, Inc.: Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living ... | ||
| BIOLINERX | 2,533 | -1,71 % | BioLineRx (BLRX) Investor Presentation - Slideshow | ||
| PROTEOSTASIS THERAPEUTICS | 0,876 | +2,31 % | PROTEOSTASIS THERAPEUTICS, INC. - 8-K, Current Report | ||
| HISTOGENICS | 0,230 | +14,38 % | Histogenics Corporation Announces Adjournment of its Special Meeting to Thursday, September 26, 2019 | ||
| FORTRESS BIOTECH | 1,611 | -0,53 % | Fortress Biotech, Inc.: Fortress Biotech to Present at September 2019 Investor Conferences | ||
| CYTODYN | 0,346 | -1,40 % | CytoDyn Inc. - 8-K, Current Report | ||
| RESTORBIO | 8,794 | +1,24 % | resTORbio, Inc.: resTORbio Reports Second Quarter 2019 Financial Results and Corporate Update |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
